We are live on
!
Find out more
FCMI
Foresite Capital Management II Portfolio holdings
AUM
$29.2M
1-Year Est. Return
44.84%
This Fund
S&P 500
This Quarter
Est. Return
+14.61%
1 Year Est. Return
+44.84%
3 Year Est. Return
-66.21%
5 Year Est. Return
-36.36%
10 Year Est. Return
–
AUM
$233M
AUM Growth
+$33.8M
(+17%)
Cap. Flow
+$8.68M
Cap. Flow
% of AUM
3.72%
Top 10 Holdings %
Top 10 Hldgs %
99.02%
Holding
13
New
4
Increased
3
Reduced
5
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DERM
Dermira, Inc.
DERM
|
+$5.98M |
| 2 |
AIMT
Aimmune Therapeutics
AIMT
|
+$3.21M |
| 3 |
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
|
+$2.54M |
| 4 |
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
|
+$1.38M |
| 5 |
Natera
NTRA
|
+$483K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NSTG
NanoString Technologies, Inc.
NSTG
|
+$3.55M |
| 2 |
Larimar Therapeutics
LRMR
|
+$887K |
| 3 |
ALDR
Alder Biopharmaceuticals
ALDR
|
+$871K |
| 4 |
AERI
Aerie Pharmaceuticals
AERI
|
+$76.8K |
| 5 |
NVET
Nexvet Biopharma plc Ordinary Shares
NVET
|
+$61.7K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 29.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AIMT
1
DELISTED
Aimmune Therapeutics
AIMT
| $86.8M | 37.22% |
3,992,517
+156,687
| +4% | +$3.21M |
|
|
AERI
2
DELISTED
Aerie Pharmaceuticals
AERI
| $71.3M | 30.6% |
1,573,026
-1,723
| -0.1% | -$76.8K |
|
|
EPZM
3
DELISTED
Epizyme, Inc
EPZM
| $26.5M | 11.35% |
1,543,118
+16,481
| +1% | +$220K |
|
|
ALDR
4
DELISTED
Alder Biopharmaceuticals
ALDR
| $19.9M | 8.53% |
956,041
-39,355
| -4% | -$871K |
|
|
NSTG
5
DELISTED
NanoString Technologies, Inc.
NSTG
| $9.79M | 4.2% |
492,539
-186,494
| -27% | -$3.55M |
|
|
DERM
6
DELISTED
Dermira, Inc.
DERM
| $6.32M | 2.71% |
+185,294
| New | +$5.98M |
|
|
NVET
7
DELISTED
Nexvet Biopharma plc Ordinary Shares
NVET
| $3.41M | 1.46% |
877,134
-17,561
| -2% | -$61.7K |
|
|
JNCE
8
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $2.64M | 1.13% |
+119,912
| New | +$2.54M |
|
|
OREX
9
DELISTED
Orexigen Therapeutics, Inc.
OREX
| $2.14M | 0.92% |
622,013
+79,258
| +15% | +$313K |
|
|
10
Larimar Therapeutics
LRMR
$416M
| $2.1M | 0.9% |
37,455
-17,860
| -32% | -$887K |
|
|
BLCM
11
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
| $1.3M | 0.56% |
+10,500
| New | +$1.38M |
|
|
XLRN
12
DELISTED
Acceleron Pharma
XLRN
| $527K | 0.23% |
19,910
| – | – |
|
|
13
Natera
NTRA
$37.5B
| $450K | 0.19% |
+50,737
| New | +$483K |
|
Similar funds
AG
SAM
AC
QI
TAAM
NAM
MSKCC
BRC
Foresite Capital Management II's Q1 2017 Portfolio in Review
As of Q1 2017, Foresite Capital Management II held 13 positions worth $233M, up 17% from $199M the previous quarter. Its ten largest holdings account for 99% of the portfolio.
Foresite Capital Management II deployed $8.68M of net new capital in Q1 2017, opening 4 new positions and adding to 3 existing holdings. Its largest new stake was Dermira, Inc.: 185,294 shares worth $6.32M.
By sector, the portfolio is most concentrated in Healthcare at 29% of assets, down from 31% a quarter earlier.
On the sell side, the largest reduction was NanoString Technologies, Inc., an estimated $3.55M trimmed.
- Foresite Capital Management II's largest Q1 2017 buy was Dermira, Inc.: 185,294 shares worth $6.32M.
- Foresite Capital Management II added most to Aimmune Therapeutics in Q1 2017, an estimated $3.21M increase.
- Foresite Capital Management II's biggest Q1 2017 reduction was NanoString Technologies, Inc., cutting an estimated $3.55M.
- Foresite Capital Management II's ten largest holdings make up 99% of its $233M portfolio in Q1 2017.
- Foresite Capital Management II opened 4 new positions and closed 0 in Q1 2017.
- Foresite Capital Management II's portfolio value rose 17% quarter-over-quarter to $233M.
Based on Foresite Capital Management II's 13F filing for Q1 2017, filed 12 May 2017.